After Oppenheimer and Citigroup gave Apellis Pharmaceuticals (NASDAQ: APLS) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Derek Archila reiterated a Buy rating on Apellis Pharmaceuticals today and set a price target of $67.00. The company’s shares closed last Thursday at $44.99.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.8% and a 46.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Apellis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $76.25, a 70.2% upside from current levels. In a report issued on April 16, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $130.00 price target.
See today’s analyst top recommended stocks >>
Apellis Pharmaceuticals’ market cap is currently $3.64B and has a P/E ratio of -9.80. The company has a Price to Book ratio of 17.76.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.
